FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990717352> ?p ?o ?g. }

• W1990717352 endingPage "413" @default.
• W1990717352 startingPage "406" @default.
• W1990717352 abstract "There is no consensus on the optimal treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) after allogeneic hematopoietic stem cell transplantation. In our center, the treatment policy has changed over time with mycophenolate mofetil (MMF) being used from 1999 to 2003, and etanercept or inolimomab after 2004. An observational study compared survival and infection rates in all consecutive patients receiving 1 of these 3 treatments. Ninety-three patients were included. The main end point was overall survival (OS). Median age was 37 years. Acute GVHD developed at a median of 15 days after transplantation. Second-line treatment was initiated a median of 12 days after aGVHD diagnosis. Therapies were MMF in 56%, inolimomab in 22%, and etanercept in 23% of the patients. Overall, second-line treatment response rate was 45% (complete response: 28%), MMF: 55%, inolimomab: 35%, and etanercept: 28%. With 74 months median follow-up, the 2-year survival was 30% (95% confidence interval: 22-41). Risk factors significantly associated with OS in multivariate analysis were disease status at transplantation; grade III-IV aGVHD at second-line treatment institution; and liver involvement. None of the second-line therapy influenced this poor outcome. Viral and fungal infections were not statistically different among the 3 treatment options; however, bacterial infections were more frequent in patients treated with anticytokines. Over an 11-year period, 3 treatment strategies, including 2 anticytokines, give similar results in patients with SR-aGVHD. There is no consensus on the optimal treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) after allogeneic hematopoietic stem cell transplantation. In our center, the treatment policy has changed over time with mycophenolate mofetil (MMF) being used from 1999 to 2003, and etanercept or inolimomab after 2004. An observational study compared survival and infection rates in all consecutive patients receiving 1 of these 3 treatments. Ninety-three patients were included. The main end point was overall survival (OS). Median age was 37 years. Acute GVHD developed at a median of 15 days after transplantation. Second-line treatment was initiated a median of 12 days after aGVHD diagnosis. Therapies were MMF in 56%, inolimomab in 22%, and etanercept in 23% of the patients. Overall, second-line treatment response rate was 45% (complete response: 28%), MMF: 55%, inolimomab: 35%, and etanercept: 28%. With 74 months median follow-up, the 2-year survival was 30% (95% confidence interval: 22-41). Risk factors significantly associated with OS in multivariate analysis were disease status at transplantation; grade III-IV aGVHD at second-line treatment institution; and liver involvement. None of the second-line therapy influenced this poor outcome. Viral and fungal infections were not statistically different among the 3 treatment options; however, bacterial infections were more frequent in patients treated with anticytokines. Over an 11-year period, 3 treatment strategies, including 2 anticytokines, give similar results in patients with SR-aGVHD." @default.
• W1990717352 created "2016-06-24" @default.
• W1990717352 creator A5004376242 @default.
• W1990717352 creator A5007202804 @default.
• W1990717352 creator A5010183839 @default.
• W1990717352 creator A5012691135 @default.
• W1990717352 creator A5017733473 @default.
• W1990717352 creator A5025781786 @default.
• W1990717352 creator A5035304691 @default.
• W1990717352 creator A5044449649 @default.
• W1990717352 creator A5066493529 @default.
• W1990717352 creator A5080673678 @default.
• W1990717352 creator A5080959881 @default.
• W1990717352 date "2012-03-01" @default.
• W1990717352 modified "2023-10-14" @default.
• W1990717352 title "Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment" @default.
• W1990717352 cites W1599864954 @default.
• W1990717352 cites W1965061580 @default.
• W1990717352 cites W1966239132 @default.
• W1990717352 cites W1966714873 @default.
• W1990717352 cites W1972097964 @default.
• W1990717352 cites W1978635205 @default.
• W1990717352 cites W1987647282 @default.
• W1990717352 cites W2012730327 @default.
• W1990717352 cites W2034081128 @default.
• W1990717352 cites W2041055738 @default.
• W1990717352 cites W2053278212 @default.
• W1990717352 cites W2053703010 @default.
• W1990717352 cites W2069251929 @default.
• W1990717352 cites W2070090685 @default.
• W1990717352 cites W2079044693 @default.
• W1990717352 cites W2088500558 @default.
• W1990717352 cites W2100125044 @default.
• W1990717352 cites W2107455630 @default.
• W1990717352 cites W2112095092 @default.
• W1990717352 cites W2123368042 @default.
• W1990717352 cites W2130373985 @default.
• W1990717352 cites W2157147843 @default.
• W1990717352 cites W2169004170 @default.
• W1990717352 cites W2312455364 @default.
• W1990717352 cites W4236572065 @default.
• W1990717352 cites W4251857914 @default.
• W1990717352 doi "https://doi.org/10.1016/j.bbmt.2011.06.012" @default.
• W1990717352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21736868" @default.
• W1990717352 hasPublicationYear "2012" @default.
• W1990717352 type Work @default.
• W1990717352 sameAs 1990717352 @default.
• W1990717352 citedByCount "85" @default.
• W1990717352 countsByYear W19907173522012 @default.
• W1990717352 countsByYear W19907173522013 @default.
• W1990717352 countsByYear W19907173522014 @default.
• W1990717352 countsByYear W19907173522015 @default.
• W1990717352 countsByYear W19907173522016 @default.
• W1990717352 countsByYear W19907173522017 @default.
• W1990717352 countsByYear W19907173522018 @default.
• W1990717352 countsByYear W19907173522019 @default.
• W1990717352 countsByYear W19907173522020 @default.
• W1990717352 countsByYear W19907173522021 @default.
• W1990717352 countsByYear W19907173522022 @default.
• W1990717352 countsByYear W19907173522023 @default.
• W1990717352 crossrefType "journal-article" @default.
• W1990717352 hasAuthorship W1990717352A5004376242 @default.
• W1990717352 hasAuthorship W1990717352A5007202804 @default.
• W1990717352 hasAuthorship W1990717352A5010183839 @default.
• W1990717352 hasAuthorship W1990717352A5012691135 @default.
• W1990717352 hasAuthorship W1990717352A5017733473 @default.
• W1990717352 hasAuthorship W1990717352A5025781786 @default.
• W1990717352 hasAuthorship W1990717352A5035304691 @default.
• W1990717352 hasAuthorship W1990717352A5044449649 @default.
• W1990717352 hasAuthorship W1990717352A5066493529 @default.
• W1990717352 hasAuthorship W1990717352A5080673678 @default.
• W1990717352 hasAuthorship W1990717352A5080959881 @default.
• W1990717352 hasBestOaLocation W19907173521 @default.
• W1990717352 hasConcept C121332964 @default.
• W1990717352 hasConcept C126322002 @default.
• W1990717352 hasConcept C141071460 @default.
• W1990717352 hasConcept C142424586 @default.
• W1990717352 hasConcept C17991360 @default.
• W1990717352 hasConcept C2777226972 @default.
• W1990717352 hasConcept C2777408962 @default.
• W1990717352 hasConcept C2779972918 @default.
• W1990717352 hasConcept C2781307858 @default.
• W1990717352 hasConcept C2909675724 @default.
• W1990717352 hasConcept C2911091166 @default.
• W1990717352 hasConcept C44249647 @default.
• W1990717352 hasConcept C71924100 @default.
• W1990717352 hasConcept C87355193 @default.
• W1990717352 hasConcept C90924648 @default.
• W1990717352 hasConceptScore W1990717352C121332964 @default.
• W1990717352 hasConceptScore W1990717352C126322002 @default.
• W1990717352 hasConceptScore W1990717352C141071460 @default.
• W1990717352 hasConceptScore W1990717352C142424586 @default.
• W1990717352 hasConceptScore W1990717352C17991360 @default.
• W1990717352 hasConceptScore W1990717352C2777226972 @default.
• W1990717352 hasConceptScore W1990717352C2777408962 @default.
• W1990717352 hasConceptScore W1990717352C2779972918 @default.
• W1990717352 hasConceptScore W1990717352C2781307858 @default.
• W1990717352 hasConceptScore W1990717352C2909675724 @default.

• next